Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...

Subsequent leukemia was associated with high cumulative doses of epipodophyllotoxins, older age at initial cancer diagnosis, and receipt of hematopoietic stem cell transplant.

San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...

A new study reveals a modular CAR-T approach that effectively targets heterogeneous antigens in paediatric acute myeloid leukaemia, enhancing treatment success through combinatorial targeting.

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment. “We are excited to announce the initiation of ...

Syndax Pharmaceuticals (NASDAQ:SNDX) fell ~23% in the premarket on Tuesday after the cancer drug developer reported topline ...

P1, the registration-directed study of luveltamab tazevibulin for pediatric patients with CBFA2T3::GLIS2 acute myeloid leukemia, has been initiated and is open for enrollment. In December 2023, Dr.

On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...

REFRaME-P1 is a registration-enabling study evaluating the efficacy and safety of luvelta in infants and children under 12 years of age with CBF/GLIS AML. This will be a global study, with the ...